Shopping Cart
Remove All
Your shopping cart is currently empty
Vixarelimab
Copy Product Info
😃Good
Catalog No. T76956Cas No. 2243320-83-2
Alias RO-7622888, RG-6536, KPL-716
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody with affinity for the beta chain of the OSM receptor, inhibiting IL-31 and OSM signaling. It can be used to study severe nodular itch and idiopathic pulmonary fibrosis.
Vixarelimab
Copy Product Info😃Good
Catalog No. T76956Alias RO-7622888, RG-6536, KPL-716Cas No. 2243320-83-2
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody with affinity for the beta chain of the OSM receptor, inhibiting IL-31 and OSM signaling. It can be used to study severe nodular itch and idiopathic pulmonary fibrosis.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $372 | In Stock | In Stock | |
| 5 mg | $997 | - | In Stock | |
| 10 mg | $1,590 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:96.5% (SDS-PAGE); 97.3% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody with affinity for the beta chain of the OSM receptor, inhibiting IL-31 and OSM signaling. It can be used to study severe nodular itch and idiopathic pulmonary fibrosis. |
| In vitro | At a concentration of 0.0001 μg/mL, Vixarelimab (KPL-716) induces an increase in MCP-1/CCL2 levels in human epidermal keratinocytes (HEK) and human dermal fibroblasts (HDF). However, at concentrations of 0.001 μg/mL or higher, there is a significant decrease in MCP-1/CCL2 levels in both cell types[1]. Pre-treatment with Vixarelimab (KPL-716) (0.0001-0.1 μg/mL) reduces MCP-1/CCL2 levels in both HEK and HDF cells induced by Oncostatin M (OSM) and OSM + IL-4. The maximum effect is observed at concentrations of 0.01 μg/mL and 0.1 μg/mL[1]. |
| Synonyms | RO-7622888, RG-6536, KPL-716 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | OSMR |
| Molecular Weight | 144.99 kDa |
| Cas No. | 2243320-83-2 |
| Isotype | IgG4 (S228P) |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Vixarelimab | purchase Vixarelimab | Vixarelimab cost | order Vixarelimab | Vixarelimab chemical structure | Vixarelimab in vitro | Vixarelimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.